Suvretta Capital Management »

Lexeo Therapeutics shares owned by Suvretta Capital Management

Quarter-by-quarter ownership of Lexeo Therapeutics (LXEO) shares owned by Suvretta Capital Management from 13F filings

Historical chart of Suvretta Capital Management investment in Lexeo Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Lexeo Therapeutics held by Suvretta Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Lexeo Therapeutics by Suvretta Capital Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $12M 1.3M 9.93

More positions owned by Suvretta Capital Management

Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Arcutis Biotherapeutics (ARQT)
Ark Etf Tr Genomic Rev Etf Put Option (ARKG)
Benitec Biopharma Com New (BNTC)
Legend Biotech Corp Sponsored Ads (LEGN)
Eyepoint Com New (EYPT)
Arcus Biosciences Incorporated (RCUS)
Immatics SHS (IMTX)
Biohaven (BHVN)
Meta Platforms Cl A (META)
Apellis Pharmaceuticals (APLS)
NVIDIA Corporation (NVDA)
Coca-Cola Company (KO)
Ge Aerospace Com New (GE)
Amazon (AMZN)

View all positions for Suvretta Capital Management

Top funds holding Lexeo Therapeutics

Henderson Group
BlackRock
Paradigm Biocapital Advisors
Vestal Point Capital
Frazier Life Sciences Management
Balyasny Asset Management
Vanguard Group
Citadel Advisors
venBio Select Advisor
Affinity Asset Advisors
Woodline Partners
State Street Corporation
Millennium Management
OrbiMed Advisors
Point72 Asset Management

View all funds holding Lexeo Therapeutics